Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results PDF Version – Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to… Read More..

SKYX Positions to Advance its Market Penetration with the AI Native E-Commerce Platform Designed to Elevate B2B and B2C Experiences Through its Innovative and Smart Product Line SKYX Continues to Grow its Builder Segment Through Direct Sales Channels and Intends to Utilize the New AI Driven Software to Enhance and… Read More..

Representative Data for Systemic Tregs and Immunomodulation Credit: Coya Therapeutics, Inc. COYA 303 is an investigational proprietary biologic combination of low-dose (LD)-IL-2 and GLP-1 receptor agonist (RA) for subcutaneous administration with potential for treating inflammation-driven diseases like Alzheimer's Disease, and other neurodegenerative and autoimmune diseases COYA 303 significantly reduced peripheral… Read More..